Sagent Pharmaceuticals Announces FDA Approval of Injectable Bupivacaine
Sagent Pharmaceuticals today announced FDA approval of bupivacaine hydrochloride injection, a local or regional anesthetic, according to a MarketWatch report.
The company's bupivacaine will be available in six single-dose and two multi-dose latex-free vials. According to IMS data, the 2011 U.S. market for injectable bupivacaine approximates $29 million.
Bupivacaine is the 13th product approved under the joint venture between Sagent and Strides Arcolab. Under the collaboration, Strides is responsible for developing and supplying injectable products that Sagent will market in the U.S.
Related Articles on Anesthesia:
Gabapentin Does Not Decrease Pain After Total Knee Arthroplasty
Popliteal Blocks Cause Rebound Pain After Ankle Fracture Surgery
Type of General Anesthesia Does Not Increase Delirium in Post-Op Period
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Latest Articles
- Distraction Reduces Perceived Pain
- Study: Nucynta Effective Pain Reliever for Diabetic Peripheral Neuropathy
- American Board of Internal Medicine Discusses Initiative to Limit Medical Tests
- Disciplinary Actions From State Medical Boards Increase
- Two Anesthesiologists Selected to Lead St. Joseph Medical Center Anesthesia Department
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,369.38 Trade time:4:03PM EDT Value change:▼73.11 (-0.59%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,778.79 Trade time:5:16PM EDT Value change:▼34.90 (-1.24%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,295.22 Trade time:4:33PM EDT Value change:▼9.64 (-0.74%)Channels
